{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.8","upperLimit":"93.2","value":"50"},{"groupId":"OG001","lowerLimit":"19.4","upperLimit":"99.4","value":"75"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"CBR is defined as percentage of participants with a confirmed Minimal response (MR) or better (i.e. MR, PR, VGPR, CR, and sCR) of best response, according to the IMWG Response Criteria. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \\<5% plasmacytomas in the bone marrow; sCR= CR as above PLUS normal serum FLC assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR \\>= 90% reduction in serum M-component plus urine M-component \\<100 mg/24 h; PR = \\>=50% reduction of serum M-protein and reduction in 24-h urinary M-protein by \\>=90% or to \\<200 mg/24 h; MR= \\>=25% but \\<=49% reduction of serum M-protein and reduction in 24-h urine M-protein by 50-89%. In addition to the above listed criteria, if present at baseline, \\>=50% reduction in the size (SPD) 4 of soft tissue plasmacytomas is also required.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 2.5 milligram (mg)/kilogram (kg) dose via intravenous (IV) infusion on Day 1 of every 21-day cycle (Q3W) maximum up to disease progression.","id":"OG000","title":"Main Study - Part 1: Belantamab Mafodotin 2.5 Milligram/ Kilogram (mg/kg)"},{"description":"Participants with RRMM received belantamab mafodotin as dose of 3.4 mg/kg via IV infusion on Day 1 of every 21-day cycle (Q3W) maximum up to disease progression.","id":"OG001","title":"Main Study - Part 1: Belantamab Mafodotin 3.4 mg/kg"}],"paramType":"NUMBER","populationDescription":"All treated population","reportingStatus":"POSTED","timeFrame":"Up to approximately 141 weeks","title":"Part 1: Clinical Benefit Rate (CBR)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}